CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

NEW DRUG APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION ACCEPTED BY THE NMPA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the new drug application for Efmedaglutide Alfa Injection (the "**Product**") developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., a subsidiary of the Company, has been accepted by the National Medical Products Administration ("**NMPA**") of the People's Republic of China. The Product has been applied as a Class 1 therapeutic biological product, and its indication is for the long-term weight management in overweight or obese adults in combination with diet control and increased physical activity.

The Product is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein injection administered once weekly. It can selectively bind to and activate GLP-1 receptors, achieving weight reduction through suppressing appetite and decreasing food intake, as well as lowering blood sugar in a glucose-dependent manner and improving cardiovascular and metabolic parameters.

This new drug application is primarily based on a pivotal Phase III clinical trial that enrolled obese or overweight adult patients with at least one weight-related comorbid condition. The results of this clinical trial showed that compared to placebo, the Product could significantly reduce body weight, and remarkably lower patients' waist circumference, blood glucose, blood pressure, blood lipids and other indicators, delivering comprehensive cardiovascular and metabolic benefits to patients. Meanwhile, the Product demonstrated favorable safety and tolerability. Compared to marketed comparators, it exhibited a lower incidence of gastrointestinal adverse events and lower rates of treatment interruption or discontinuation due to adverse events. In addition, its dose escalation regimen was faster and simpler, with the target maintenance dose achieved within just 4 weeks.

Currently, two Phase III clinical trials of the Product in patients with type 2 diabetes are actively underway, with the aim of benefiting more patients.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 13 October 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.